Salvia BioElectronicsAnnounced the successful completion of its $60 million (€53 million) Series B financing round. This round of financing was led byInnovation Industries led the round, with participation from Invest-NL, EIC Fund, Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM), and Thuja Capital. The funds raised in this round will primarily be used to complete its productMySalviaClinical Researchand used to supportSubsequent Commercialization。
"Salvia is reshaping the migraine treatment landscape with a bold, patient-centric strategy that combines cutting-edge neuromodulation technology with elegant, minimally invasive design. We are committed to investing in breakthrough technologies that address significant real-world challenges, and Salvia is delivering life-changing solutions for millions of patients suffering from chronic migraine. We look forward to partnering with the Salvia team to advance clinical development and bring this profoundly impactful new therapy to patients as soon as possible."---Caaj Greebe Partner, Innovation Industries"Backed by a powerful investment consortium, we are poised to bring MySalvia therapy to patients in urgent need of new treatment options. Chronic migraine is far from an 'ordinary headache'; it is a debilitating neurological disease that forces patients to withdraw from social interactions, work, and their desired quality of life. Our mission is to help them regain freedom—MySalvia therapy aims not only to alleviate symptoms but also to create profound and lasting positive impacts. We firmly believe that migraine patients deserve the opportunity to restart their lives. This round of financing will accelerate regulatory approval and commercialization processes, with the ultimate goal of benefiting millions of chronic migraine patients worldwide."---Hubert Martens Founder and CEO of Salvia BioElectronicsMigraine is a common primary headache in clinical practice, characterized by recurrent episodes of moderate to severe pulsating headache, often accompanied by symptoms such as nausea or vomiting, photophobia, and phonophobia. Migraine has a high prevalence and a long disease course, ranking second in the burden of neurological diseases.Migraine, although not an immediately life-threatening disease, due to itsHigh incidence, prolonged disease course, andLong-term recurrent episodes. Impact on the patient's physical healthhealth, quality of life, and other products are severely affected. According to"The Lancet"The released "2019 Global Burden of Disease Study" report shows:Years Lived with Disability (YLDs) Due to Migraine Rank Second Among All Diseases GloballyThe population of migraine patients is vast: approximately 1.04 billion people worldwide suffer from migraines, with a lifetime prevalence of about 10% in men and 22% in women. Annually, onlyThe annual treatment cost for patients diagnosed with migraine exceeds 299.4 billion yuan. It can be said thatMigraineExerts a profoundly negative impact on patients, their families, and society.
Although there are increasingly more technologies available for treating migraines, current treatments fail to adequately alleviate symptoms. Most chronic patients discontinue medication within the first year, and this high dropout rate underscores the urgent need for alternative therapies.
MySalviaConsisting of two types of ultra-thin implantable electrodes andExternal wearable device composition.Two ultra-thin implantable electrodes: one placed under the skin of the forehead, and the other under the skin at the back of the head, therebyForming a Targeted Neuromodulation Network. Patients can initiate migraine treatment through external wearable devices.Throughout the treatment process, the patient is entirely “autonomous,” i.e., the patientViaMySalviaWearable devices enable one-touch activation of therapy, delivering precise neuromodulation at the desired time and location.MySalvia Mechanism of ActionMySalviaand"Neuromodulation" Technical PrinciplesSimilar principle (traditionalThe technology of "neuromodulation" has been validated for decades in the treatment of neurological disorders such as Parkinson's disease and epilepsy.Salvia BioElectronics creatively applied this technology to the field of migraine treatment.MySalviaSignificantly reduces the frequency and intensity of migraine attacks by delivering mild electrical pulses to migraine-related nerves via implantable electrodes.The human nervous system regulates bodily movement, sensation, and function through electrical signals. In healthy individuals, migraines often occur due to abnormalities in neural signal transmission.MySalviaNeuromodulation technology helps restore the balance of neural signals through precise intervention, thereby addressing patients' abnormalNeural signal conduction returns to normal.According toSalvia BioElectronics AnnouncesMySalviaEarly research data show that,MySalviaReduces the intensity and frequency of migraine attacks.Minimally Invasive: Reduced surgical complexity and shortened recovery period
Concealment: Ultra-thin design achieves a visually seamless appearance
Autonomy: Patients trigger precise stimulation on demand via wearable devices
Salvia BioElectronics
Salvia BioElectronicsis an innovative medical device company with the mission to "empower chronic migraine patients to regain control of their lives," developing revolutionary therapies through targeted neuromodulation technology.MySalviaThe therapy employs an ultra-thin implant to achieve precise neural intervention.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)